Assignee
ACTINIUM PHARMACEUTICALS INC
US·19 granted patents·40 pending applications·34 citations·filing 2001–2025
Top patents by PatentIndex Score
59 records- 0190US11844799B2Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeuticACTINIUM PHARMACEUTICALS INC·Filed 2022·Granted Dec 19, 2023·2 cites·2 claims
- 0289US9790573B2Method for purification of 225AC from irradiated 226RA-targetsACTINIUM PHARMACEUTICALS INC·Filed 2016·Granted Oct 17, 2017·10 cites·22 claims
- 0386US11364235B2Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeuticACTINIUM PHARMACEUTICALS INC·Filed 2018·Granted Jun 21, 2022·4 cites·18 claims
- 0482US12133849B2Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting radioimmunotherapeuticACTINIUM PHARMACEUTICALS INC·Filed 2023·Granted Nov 5, 2024·0 cites·7 claims
- 0581US2025017919A1Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeuticACTINIUM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0678US9534277B1Method for purification of 225AC from irradiated 226RA-targetsACTINIUM PHARMACEUTICALS INC·Filed 2014·Granted Jan 3, 2017·4 cites·22 claims
- 0777US11292835B2Low dose antibody-based methods for treating hematologic malignanciesACTINIUM PHARMACEUTICALS INC·Filed 2017·Granted Apr 5, 2022·1 cites·6 claims
- 0877US8349391B2Radium target and method for producing itACTINIUM PHARMACEUTICALS INC·Filed 2006·Granted Jan 8, 2013·9 cites·44 claims
- 0976US11975081B2Bifunctional chelators and conjugatesACTINIUM PHARMACEUTICALS INC·Filed 2023·Granted May 7, 2024·0 cites·26 claims
- 1076US11964948B2Bifunctional chelators and conjugatesACTINIUM PHARMACEUTICALS INC·Filed 2023·Granted Apr 23, 2024·0 cites·23 claims
- 1175US11241512B2Stabilized radio-labeled anti-CD45 immunoglobulin compositionsACTINIUM PHARMACEUTICALS INC·Filed 2019·Granted Feb 8, 2022·0 cites·8 claims
- 1275US2022118122A1Stabilized radiolabeled anti-cd45 immunoglobulin compositionsACTINIUM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1372US2024408250A1Methods for treatment of patients with myelodysplastic syndromesACTINIUM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1471US11912780B2Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapiesACTINIUM PHARMACEUTICALS INC·Filed 2018·Granted Feb 27, 2024·1 cites·25 claims
- 1571US7374936B2Method and means for site directed therapyACTINIUM PHARMACEUTICALS INC·Filed 2001·Granted May 20, 2008·3 cites·9 claims
- 1671US2024254092A1Bifunctional chelators and conjugatesACTINIUM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1768US12410249B2Low dose antibody-based methods for treating hematologic malignanciesACTINIUM PHARMACEUTICALS INC·Filed 2022·Granted Sep 9, 2025·0 cites·13 claims
- 1868US11981741B2Humanized anti-CD45 antibodiesACTINIUM PHARMACEUTICALS INC·Filed 2023·Granted May 14, 2024·0 cites·11 claims
- 1968US2008279772A1Methods for detecting pathological sitesACTINIUM PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 2067US2025121105A1Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugatesACTINIUM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2166US2026053963A1Radioconjugates targeting cd33 in the treatment of breast cancerACTINIUM PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2265US12491274B2Radioconjugates targeting CD33 in the treatment of sarcomasACTINIUM PHARMACEUTICALS INC·Filed 2022·Granted Dec 9, 2025·0 cites·2 claims
- 2365US2009191122A1Method for purification of 225ac from irradiated 226ra-targetsACTINIUM PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 2464US2024158528A1Anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapiesACTINIUM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2563US2024301081A1Humanized anti-cd45 antibodiesACTINIUM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2661US12083192B2Methods for treatment of patients with myelodysplastic syndromesACTINIUM PHARMACEUTICALS INC·Filed 2018·Granted Sep 10, 2024·0 cites·18 claims
- 2759US2013266475A1Method for purification of 225ac from irradiated 226ra-targetsACTINIUM PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 2858US2025205375A1Her3 radioimmunotherapy for the treatment of solid cancersACTINIUM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2957US12539340B2Radioconjugates targeting CD33 in the treatment of cancersACTINIUM PHARMACEUTICALS INC·Filed 2022·Granted Feb 3, 2026·0 cites·18 claims
- 3056US12447218B1Radioconjugates directed to MHC-complexed antigens in cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Granted Oct 21, 2025·0 cites·4 claims
- 3156US2025073274A1Methods for treating cd33-positive hematological malignanciesACTINIUM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3256US2025281654A1Methods for treating cancer using combinations of epigenetic therapies and radioconjugate targeting agentsACTINIUM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3355US2023416348A1Calreticulin nanobodiesACTINIUM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3455US2025289875A1Grp78 nanobodiesACTINIUM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3554US2026000795A1Her3 nanobodiesACTINIUM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3654US2023248855A1Her3 radioimmunotherapy for the treatment of solid cancersACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3753US2022251239A1Combination radioimmunotherapy and cd47 blockade in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3853US2022288244A1Combination radioimmunotherapy and cd47 blockade in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3952US2022211886A1Combination radioimmunotherapy and cd47 blockade in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4051US2024299600A1Method for treating acute myeloid leukemia using venetoclax in conjunction with lintuzumab-ac225ACTINIUM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4151US2024390532A1Radioimmunoconjugates targeting grp78 for use in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4251US2024216554A1Radioimmunoconjugates directed to nkg2d ligands for the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4350US12551584B1Lewis Y radioimmunotherapy for the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2021·Granted Feb 17, 2026·0 cites·7 claims
- 4450US2025339571A1Radioimmunoconjugates targeting phosphatidylserine for use in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4549US2024226345A1Radioimmunoconjugates targeting calreticulin for use in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4649US2022143228A1Her3 radioimmunotherapy for the treatment of solid cancersACTINIUM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4749US2022072167A1Methods for Treating Cancer Using Combinations of PARP Inhibitors and Antibody RadioconjugatesACTINIUM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4848US2020338219A1Molecules and their derivatives directed aganist cd45ACTINIUM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4948US2024197931A1Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cellsACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 5048US2022211885A1Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseasesACTINIUM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
Showing the top 50 of 59 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →